- Home
- THTX vs TARA Comparison
THTX vs TARA Comparison
Compare THTX & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THTX
- TARA
- Stock Information
- Founded
- THTX 1993
- TARA N/A
- Country
- THTX Canada
- TARA United States
- Employees
- THTX N/A
- TARA N/A
- Industry
- THTX Biotechnology: Pharmaceutical Preparations
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- THTX Health Care
- TARA Health Care
- Exchange
- THTX Nasdaq
- TARA Nasdaq
- Market Cap
- THTX 144.8M
- TARA 118.1M
- IPO Year
- THTX N/A
- TARA N/A
- Fundamental
- Price
- THTX $3.20
- TARA $3.13
- Analyst Decision
- THTX Hold
- TARA Strong Buy
- Analyst Count
- THTX 1
- TARA 7
- Target Price
- THTX N/A
- TARA $20.67
- AVG Volume (30 Days)
- THTX 260.8K
- TARA 204.1K
- Earning Date
- THTX 07-09-2025
- TARA 08-12-2025
- Dividend Yield
- THTX N/A
- TARA N/A
- EPS Growth
- THTX N/A
- TARA N/A
- EPS
- THTX N/A
- TARA N/A
- Revenue
- THTX $84,378,000.00
- TARA N/A
- Revenue This Year
- THTX N/A
- TARA N/A
- Revenue Next Year
- THTX $13.76
- TARA N/A
- P/E Ratio
- THTX N/A
- TARA N/A
- Revenue Growth
- THTX 2.19
- TARA N/A
- 52 Week Low
- THTX $1.12
- TARA $1.60
- 52 Week High
- THTX $3.22
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- THTX 71.13
- TARA 48.33
- Support Level
- THTX $2.28
- TARA $3.06
- Resistance Level
- THTX $3.22
- TARA $3.18
- Average True Range (ATR)
- THTX 0.02
- TARA 0.16
- MACD
- THTX -0.02
- TARA -0.02
- Stochastic Oscillator
- THTX 68.75
- TARA 21.22
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).